top of page
ADELA
PHASE III TRIAL RANDOMIZED TRIAL OF ELACESTRANT PLUS EVEROLIMUS VERSUS ELACESTRANT IN PATIENTS WITH ER+/HER2- ESR-MUTATED ADVANCED BREAST CANCER REFRACTORY TO CDK4/6 INHIBITORS PLUS ENDOCRINE THERAPY
CLINICAL TRIAL DETAILS
A RANDOMIZED PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ELACESTRANT PLUS EVEROLIMUS VERSUS ELACESTRANT IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE, ESR1-MUTATED, ADVANCED BREAST CANCER PROGRESSING TO ENDOCRINE THERAPY AND CDK4/6 INHIBITORS.
COUNTRY
STATUS
TUMOR TYPE
PHASE
N
SITES
ER+/HER2- ABC
110
240
III
Austria, Brazil, Czech Republic, Spain, France, Greece, Italy, Germany, UK
Recruiting
PRESS RELEASE
----
SCIENTIFIC IMPACT
BLOG ARTICLES RELATED
----
TRIAL SITES
----
Dr. Cortes and Dr. Llombart PHERain interview
Beyond Chemotherapy
Dr. Vanes Quiroga
Dr. Sofia Braga
Dr. Silvi AntolÃn
Dr. Escrivá de RomanÃ
Dr. Philipp Aftimos
Dr. Manuel Ruiz
Prof. Daniele Generali PHEGain interview
Dr. Jacques Medioni
Dr. Dunca Wheatley
bottom of page